Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study.

Rachel WuerstleinR KatesO GluzE M GrischkeC SchemM ThillS HasmuellerA KöhlerB OtrembaF GriesingerC SchindlbeckA TrojanF OttoM KnauerR PuschN Harbecknull null

Published in: Breast cancer research and treatment (2019)

MammaPrint and BluePrint test results strongly impacted physicians' therapy decisions in luminal EBC with up to three involved lymph nodes. The high adherence to genetically determined risk assessment represents a key prerequisite for achieving a personalized cost-effective approach to disease management of early breast cancer.

Keyphrases

early breast cancer
lymph node
risk assessment
primary care
human health
heavy metals
stem cells
early stage
neoadjuvant chemotherapy
replacement therapy
skeletal muscle
cell therapy
glycemic control